AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06074497 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KGX101- Cohort 1
Description: Single dose of 0.3, 1.0, 3.0μg/kg of KGX101 every 3 weeks
Study NCT06613945 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ERCP biliary drainage
Description: bilateral metallic stents insertion will be attempted through ERCP to secure biliary drainage
Study NCT06613945 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Combined ERCP and EUS-HGS biliary drainage
Description: unilateral metallic stent will be inserted on right side by ERCP and a hepaticogastrostomy transmural stent will be inserted on left side by EUS to secure biliary drainage.
Study NCT05854992 — intervention group
Intervention type: DRUG
Intervention: Acute migraine treatment with any prescribed triptans
Description: Sumatriptan, treximet (sumatriptan/naproxen combination), zolmitriptan, naratriptan, rizatriptan, almotriptan, eletriptan, and frovatriptan. No restriction on dose, frequency, duration, or delivery routes.
Study NCT06173934 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin injection 15 minutes before meals
Description: Adjust insulin injection time to observe blood glucose spectrum
Study NCT06173934 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin injection 15 minutes after eating
Description: Adjust insulin injection time to observe blood glucose spectrum
Study NCT05053711 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS+rPMS_iTBS_M
Description: Repetitive peripheral magnetic stimulation (rPMS) intermittent theta-burst stimulation pattern (iTBS) will intermittently give a 2 s train of iTBS every 10s repeated 2 times for a total of 40 times at median nerve on the affected hand(low pulse: 1200 pulses in total). Then following Repetitive transcranial magnetic stimulation (rTMS) will intermittently give a 2 s train of iTBS every 10s repeated 2 times for a total of 40 times on affected hemisphere(low pulse: 1200 pulses in total).
Study NCT02371096 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MabThera (rituximab)
Study NCT05053711 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS+rPMS_cTBS_M
Description: Repetitive peripheral magnetic stimulation (rPMS) continuous burst stimulation pattern (cTBS) will intermittently give a cTBS treatment consists of a continuous train of TBS for 40 seconds repeated for 2 times at median nerve on the affected hand(low pulse: 1200 pulses in total). Then following Repetitive transcranial magnetic stimulation (rTMS) will intermittently give a 2 s train of iTBS every 10s repeated 2 times for a total of 40 times on affected hemisphere(low pulse: 1200 pulses in total).
Study NCT05053711 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: rTMS+sham rPMS_M
Description: Repetitive peripheral magnetic stimulation (rPMS) sham burst stimulation pattern (sham TBS) will intermittently give a sham TBS treatment consists of a continuous train of TBS for 40 seconds at median nerve on the affected hand(almost no pulse: 1200 pulses in total). Then following Repetitive transcranial magnetic stimulation (rTMS) will intermittently give a sham TBS treatment consists of a continuous train of TBS for 40 seconds on affected hemisphere(almost no pulse: 1200 pulses in total).
Study NCT05053711 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS+rPMS_iTBS_U
Description: Repetitive peripheral magnetic stimulation (rPMS) intermittent theta-burst stimulation pattern (iTBS) will intermittently give a 2 s train of iTBS every 10s repeated 2 times for a total of 40 times at ulnaris nerve on the affected hand(low pulse: 1200 pulses in total). Then following Repetitive transcranial magnetic stimulation (rTMS) will intermittently give a 2 s train of iTBS every 10s repeated 2 times for a total of 40 times on affected hemisphere(low pulse: 1200 pulses in total).
Study NCT05053711 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS+rPMS_cTBS_U
Description: Repetitive peripheral magnetic stimulation (rPMS) continuous burst stimulation pattern (cTBS) will intermittently give a cTBS treatment consists of a continuous train of TBS for 40 seconds repeated for 2 times at ulnar nerve on the affected hand(low pulse: 1200 pulses in total). Then following Repetitive transcranial magnetic stimulation (rTMS) will intermittently give a 2 s train of iTBS every 10s repeated 2 times for a total of 40 times on affected hemisphere(low pulse: 1200 pulses in total).
Study NCT05053711 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: rTMS+sham rPMS_U
Description: Repetitive peripheral magnetic stimulation (rPMS) sham burst stimulation pattern (sham TBS) will intermittently give a sham TBS treatment consists of a continuous train of TBS for 40 seconds at ulnar nerve on the affected hand(almost no pulse: 1200 pulses in total). Then following Repetitive transcranial magnetic stimulation (rTMS) will intermittently give a sham TBS treatment consists of a continuous train of TBS for 40 seconds on affected hemisphere(almost no pulse: 1200 pulses in total).
Study NCT05469932 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Rexon device
Description: Rexon device for 20 minutes each session. A total of 4 sessions with one week apart from each other.
Study NCT05469932 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Rexon device
Description: Rexon device for 20 minutes each session. A total of 4 sessions with one week apart from each other.
Study NCT05438784 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: orbital bone reconstruction with patient specific titanium implant
Description: orbital defects reconstruction will be virtually planned by software and a patient specific titanium implant will be manufactured using milling technique depending on CAD-CAM technology
Study NCT05438784 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: orbital bone reconstruction with preformed titanium plate preoperatively bended on stereolithographic model
Description: orbital defects reconstruction will be virtually planned by software and a reconstructed stereolithographic model will be 3D printed and used for preoperatively bending of preformed titanium implant.
Study NCT02371096 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RGB-03
Study NCT06074497 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KGX101- Cohort 2
Description: Single dose of 1, 1 and 3μg/kg of KGX101 every 3 weeks
Study NCT06074497 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KGX101- Cohort 3
Description: Single dose of 1,3 and 6μg/kg of KGX101 every 3 weeks
Study NCT05139082 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: TQB3616 capsules＋ TQB2450 injection
Description: TQB3616 is a highly active CDK4/6 inhibitor. Preclinical studies have shown that it has a strong inhibitory effect on the kinase activity of CDK4/6.~TQB2450 is a humanized monoclonal antibody targeting PD-L1, which prevents PD-L1 from binding to the PD-1 and B7.1 receptors on the surface of T cells, so as to restore the activity of T cells and thereby enhance the immune response, and has the potential to treat various types of tumors.
Study NCT05515471 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR8058 eye drops
Description: SHR8058 eye drops
Study NCT05515471 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline eye drops.
Description: saline eye drops.
Study NCT05290792 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Administration of FluMist (Live Attenuated Influenza Vaccine)
Description: Participants will received the intranasal FluMist vaccine that will serve as a proxy for a viral respiratory tract infection and trigger a mild immune response.
Study NCT06557486 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Stress reduction
Description: Participants assigned to the 8-week mindfulness program attended weekly 120-150 minute in-person group sessions for the entire duration. In these sessions, the instructor progressively will introduce and guide formal mindfulness practices while facilitating the sharing of experiences.
Study NCT05482542 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Autologous hematopoietic stem cell transplantation
Description: Autologous hematopoietic stem cell transplantation
Study NCT05482542 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Cyclophosphamide/ATG
Description: Cyclophosphamide/ATG
Study NCT05482542 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Cyclophosphamide/Rituximab
Description: Cyclophosphamide/Rituximab
Study NCT05854992 — intervention group
Intervention type: DRUG
Intervention: Standard of care management of acute migraine without triptans
Description: Any standard of care management without triptans
Study NCT06622031 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transjugular intrahepatic portosystemic shunt
Description: A needle punctured the portal vein through the transjugular approach. After a successful puncture, the parenchymal tract was dilated, and covered stents were introduced. The specifications of the covered stents were 8 mm × 50 mm, 8 mm × 60 mm, 8 mm × 70 mm, and 8 mm × 80 mm. All of the diameters of the bare stents were 8 mm, and the lengths were 50-80 mm. The portal vein pressure was measured before and after shunt creation. After the insertion of TIPS, all of the participants received a diuretic treatment and a salt-limited diet.
Study NCT06622031 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: 12 mg (body weight ≥60 kg) , 8 mg (body weight \<60 kg
Study NCT02080910 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychoeducation
Study NCT05107427 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MRx0518
Description: MRx0518 is a live biotherapeutic product consisting of a lyophilised formulation of a proprietary strain of bacterium. The study dosing regimen is one capsule two times per day for the duration of the treatment period.
Study NCT05107427 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Avelumab 20 mg/mL Intravenous Solution (IV)
Description: Avelumab is an IV administered monoclonal antibody that blocks the interaction of programmed death ligand-1 (PD-L1) with its receptors PD-1 and B7.1 on T cells and antigen-presenting cells, and has been shown to activate adaptive and innate immune functions.~The study dosing regimen is 800 mg (four 20mL vials of 20mg/mL solution) for IV infusion once every two weeks
Study NCT06428682 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Description: Experimental group will receive TXA intraoperatively (15mg/kg IV, once at beginning of case then re dose at 4hrs if operation goes longer) at the time of their surgery.
Study NCT06622031 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1 inhibitor
Description: Tislelizumab (200mg intravenously every 3 weeks), Sintilimab (200mg intravenously every 3 weeks), Camrelizumab (200mg intravenously every 3 weeks)
Study NCT06428682 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Control group will receive same volume equivalent of saline intravenously at the time of their surgery.
Study NCT06074497 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KGX101- Cohort 4
Description: Single dose of 1,3,12μg/kg of KGX101 every 3 weeks
Study NCT06074497 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KGX101- Cohort 5
Description: Single dose of 2, 5 and 15 μg/kg of KGX101 every 3 weeks
Study NCT05464550 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Eye tracker
Description: Eye movements on a screen are captured with an eye tracker during a repeated measures before/after a directed autobiographical recall.
Study NCT06614257 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LG-TAP block with local anesthetic
Description: The laparoscopic guided TAP Block was performed by surgeon at the beginning of surgery, injecting 15 ml of Ropivacaine 0.5% on each side, using an atraumatic needle (10/15 cm length, 20 Gauge diameter) close to the anterior axillary line, between the iliac crest and the subcostal margin. Correct needle tip positioning between the transverse muscle of the abdomen and the internal oblique was verified through laparoscopic guidance.
Study NCT06614257 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Port site infiltration
Description: Prior the surgical incision, an infiltration of the laparoscopic access using a total of 10 ml Ropivacaine 0.5% was performed by surgeon
Study NCT06614257 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Port site infiltration
Description: Prior the surgical incision, an infiltration of the laparoscopic access using a total of 10 ml Ropivacaine 0.5% was performed by surgeon
Study NCT06614257 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: LG-TAP block with saline solution
Description: The laparoscopic guided TAP Block was performed by surgeon at the beginning of surgery, injecting 15 ml of Saline solution (NaCl 0.9%) on each side, using an atraumatic needle (10/15 cm length, 20 Gauge diameter) close to the anterior axillary line, between the iliac crest and the subcostal margin. Correct needle tip positioning between the transverse muscle of the abdomen and the internal oblique was verified through laparoscopic guidance.
Study NCT06389786 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bilateral Pelvic Lymph Node Dissection
Description: Undergo bilateral pelvic lymph node dissection
Study NCT06389786 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo tissue sample collection
Study NCT06389786 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Scan
Description: Undergo bone scan
Study NCT06389786 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT
Study NCT06389786 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic Health Record Review
Description: Ancillary studies
Study NCT06389786 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Flotufolastat F-18 Gallium
Description: Given IV
Study NCT06389786 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic Radical Prostatectomy with Robotics
Description: Undergo robotic radical prostatectomy
Study NCT06389786 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI or PET/MRI
Study NCT06389786 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/MRI
Study NCT05129423 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MTPS9579A
Description: MTPS9579A will be administered.
Study NCT04684511 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRM-201 (Rofecoxib)
Description: Eligible patients will be randomized to receive TRM-201 or placebo
Study NCT04684511 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Placebo
Study NCT06622499 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ringer's Lactate
Description: On the first trial day healthy volunteers are randomized to receive 1 liter of Ringer's lactate either cold (10°C, 50°F), or at room temperature (22°C, 71.6°F) with 100 ml/min. After a minimum washout period of 24 hours, subjects are switched to receive infusion at the other aforementioned temperatures.
Study NCT05129423 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matched with MTPS9579A will be administered.
Study NCT05229978 — intervention group
Intervention type: OTHER
Intervention: Showing an existing Dynamic Consent (computer interface) as prompt
Description: An existing Dynamic Consent interface will be shown as a prompt halfway through the focus group sessions.
Study NCT04840069 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluciclovine PET guided Radiotherapy
Description: PET+MRI Based There is no GTV_5400. The GTV_6000 will be defined as the surgical cavity inclusive of any remaining tumor enhancement and the hypermetabolic volume. CTV_5400 will include the GTV_6000 plus a margin of 1.0 cm which may be reduced around natural barriers to tumor growth such as the skull, ventricles, falx, etc. CTV_5400 must also include the entirety of the GTV_6000. There is no CTV_6000. PTV_5400 is the CTV_5400 plus a geometric 3 mm expansion in all dimensions; PTV_6000 is GTV_6000 plus a geometric 3 mm expansion in all dimensions. PTV may extend beyond bony margins and the skin surface. The PTV_5400 must contain the PTV_6000. In the setting of multi-focal disease, the primary target volumes will be defined as above, but for satellite lesions, the GTV_6000 will be defined as any tumor enhancement and hypermetabolic volume. There will be no CTV_6000. PTV_6000 will be defined as GTV_6000 plus a geometric 3 mm expansion in all dimensions.
Study NCT06019949 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcutaneous spinal cord stimulator
Description: Stimulation to the spinal cord will be administered using Neostim/Biostim (Cosyma Inc., Denver CO) device by applying up to five conductive electrodes placed on the skin at the midline over the thoracic levels as cathodes between T1 to T8, and up to four self-adhesive electrodes located symmetrically on the skin over the iliac crests and shoulders as anodes.
Study NCT06019949 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous spinal cord stimulator
Description: Stimulation to the spinal cord will be administered using Neostim/Biostim (Cosyma Inc., Denver CO) device by applying up to five conductive electrodes placed on the skin at the midline over the thoracic levels as cathodes between T1 to T8, and up to four self-adhesive electrodes located symmetrically on the skin over the iliac crests and shoulders as anodes.
Study NCT06019949 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Respiratory Training
Description: Standard threshold Positive Expiratory Pressure Device (PEP, Respironics Inc., Cedar Grove, NJ) and standard threshold Inspiratory Muscle Trainer (IMT, Respironics Inc., Cedar Grove, NJ) assembled together using a T-shaped connector with a flanged mouthpiece (Airlife 001504) will be used for the respiratory training intervention.
Study NCT06019949 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Respiratory Training
Description: Standard threshold Positive Expiratory Pressure Device (PEP, Respironics Inc., Cedar Grove, NJ) and standard threshold Inspiratory Muscle Trainer (IMT, Respironics Inc., Cedar Grove, NJ) assembled together using a T-shaped connector with a flanged mouthpiece (Airlife 001504) will be used for the respiratory training intervention.
Study NCT06631573 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: fixed all-on-four prosthesis reinforced with PEEK framework.
Description: Prosthetic rehabilitation of mandibular edentulous arches with fixed all-on-four prosthesis reinforced with PEEK framework.
Study NCT06631573 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fixed all-on-four prosthesis reinforced with Co-Cr framework
Description: Prosthetic rehabilitation of mandibular edentulous arches with fixed all-on-four prosthesis reinforced with Co-Cr framework
Study NCT06629558 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Silver Nitrate
Description: bronchoscopic lung volume reduction in management of localized emphysema
Study NCT06629558 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nano-silver nitrate
Description: bronchoscopic lung volume reduction in management of localized emphysema
Study NCT06629558 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bronchoscopic lung volume reduction
Description: bronchoscopic lung volume reduction in management of localized emphysema
Study NCT06631196 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Jacobson's PMRT
Description: each child in the intervention group will perform five sessions of Jacobson's PMRT. Each session lasted for 15-20 minutes under the supervision of the researcher.
Study NCT06632067 — intervention group
Intervention type: DRUG
Intervention: sugammadex
Description: sugammadex used for neuromuscular reversal
Study NCT04767620 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rugdenzengsheng No. 1 prescription
Description: The study group was treated with the No. 1 Mammary Gland Growth Recipe orally, a total of 1 course of treatment, each course of 14 days, avoiding the menstrual period. The specific composition of Mammary Gland Hyperplasia No. 1 Recipe: Angelica 10g, Radix Paeoniae Alba 10g, Atractylodes Macrocephala 10g, Ginger 3g, Peppermint 6g, Vinegar Green Peel 6g, Lychee Seed 12g, Tangerine Seed 10g, Corydalis 10g, Fritillaria 6g, Trichosanthis 10g, Kombu 20g , Mustard seeds 10g, Moutan bark 6g, Poria 10g, North Bupleurum 6g. Method of administration: 14 doses in total, taken twice a day. The medicine is formulated in the herbal medicine room of the Affiliated Hospital of Qinghai University, with strict quality control.
Study NCT06632067 — intervention group
Intervention type: DRUG
Intervention: Neostigmine + Atropine
Description: Neostigmine and Atropine used for neuromuscular reversal
Study NCT05273307 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Miraculin
Description: Given orally
Study NCT05273307 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Miracle Fruit Placebo Cube
Description: Given orally